Global Meloxicam Drug Market Size By Type (Tablet, Capsule), By Application (Osteoarthritis in adults (OA), Rheumatoid Arthritis in adults (RA)), By Region, And Segment Forecasts, 2023 to 2032

The Global Meloxicam Drug Market was valued at USD 1.7 billion in 2023 and is projected to reach USD 2.9 billion by 2031, growing at a CAGR of 6.8% during the forecast period from 2023 to 2031. The market is primarily driven by the rising prevalence of osteoarthritis and rheumatoid arthritis, increasing geriatric population, and the expanding use of nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management. Meloxicam, known for its COX-2 selectivity, offers anti-inflammatory, analgesic, and antipyretic benefits, which make it a preferred treatment option among clinicians globally.

Drivers:

1. Growing Burden of Arthritis and Chronic Pain Disorders

The rising number of patients diagnosed with arthritis and other chronic musculoskeletal conditions is fueling demand for effective and tolerable pain relief solutions like meloxicam. This trend is particularly significant in aging populations.

2. Cost-Effective Generic Availability

Widespread availability of meloxicam as a low-cost generic drug has significantly increased its accessibility in both developed and emerging markets, making it a cornerstone in the treatment of inflammatory pain.

3. Favorable Prescription Trends and Physician Endorsement

Healthcare professionals are increasingly prescribing meloxicam due to its once-daily dosing and gastrointestinal tolerability compared to other NSAIDs, reinforcing its market adoption.

Restraints:

1. Side Effects and Cardiovascular Risk Concerns

Although meloxicam is generally well tolerated, its long-term use may be associated with gastrointestinal, renal, and cardiovascular side effects, limiting prolonged prescriptions and prompting some regulatory restrictions.

2. Market Saturation from Competing NSAIDs

The availability of multiple over-the-counter and prescription NSAIDs poses stiff competition, potentially affecting market share and pricing for meloxicam-based products.

Opportunity:

1. Rising Geriatric Population Worldwide

The increasing elderly population is a key opportunity, as this group represents a major consumer base for anti-inflammatory and analgesic drugs due to higher incidences of joint disorders and age-related inflammation.

2. Emerging Markets Expansion

Emerging economies in Asia-Pacific, Latin America, and Africa are witnessing better access to healthcare and a growing demand for effective and affordable anti-inflammatory medications, opening new avenues for meloxicam drug manufacturers.

Market by System Type Insights:

Tablet formulations held the largest market share in 2023, driven by their convenience, cost-efficiency, and patient adherence. The oral suspension segment is projected to grow rapidly, especially among pediatric and geriatric patients who require flexible dosing and easier administration.

Market by End-use Insights:

Hospital pharmacies emerged as the leading distribution channel in 2023, accounting for a significant portion of meloxicam sales due to the volume of inpatient prescriptions. However, retail pharmacies and online pharmacies are expected to witness notable growth, owing to improved patient access and rising digital adoption in the pharmaceutical sector.

Market by Regional Insights:

North America dominated the meloxicam drug market in 2023, driven by high diagnosis rates of arthritis, strong healthcare infrastructure, and insurance coverage. Asia-Pacific is anticipated to record the fastest growth during the forecast period, supported by increasing healthcare spending, expanding patient population, and greater awareness about chronic pain management.

Competitive Scenario:

Key players in the Global Meloxicam Drug Market include Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Mylan N.V., Hikma Pharmaceuticals, Zydus Lifesciences, Dr. Reddy’s Laboratories, Pfizer Inc., and Sun Pharmaceutical Industries Ltd. These companies are focusing on increasing market share through new product launches, strategic distribution partnerships, and geographical expansion. For example:

In 2024, Teva introduced a fast-dissolving meloxicam tablet in the U.S. to improve compliance in elderly patients.

In 2023, Zydus Lifesciences gained regulatory approval for its meloxicam injection product across key Asian markets.

Scope of Work – Global Meloxicam Drug Market

Key Market Developments:

March 2023: Mylan launched meloxicam oral suspension across Southeast Asia, targeting improved uptake in pediatric rheumatology.

July 2024: Boehringer Ingelheim announced clinical trials for a new fixed-dose combination therapy including meloxicam and paracetamol to enhance analgesic efficacy.

January 2025: Hikma Pharmaceuticals expanded its injectable meloxicam production facility to meet rising global demand.

FAQs:

1. What is the current market size of the Global Meloxicam Drug Market?

The market was valued at USD 1.7 billion in 2023.

2. What is the major growth driver of the Global Meloxicam Drug Market?

The major growth driver is the increasing prevalence of arthritis and the demand for affordable anti-inflammatory treatment.

3. Which is the largest region during the forecast period in the Global Meloxicam Drug Market?

North America is the largest region in 2023, while Asia-Pacific is expected to see the fastest growth through 2031.

4. Which segment accounted for the largest market share in the Global Meloxicam Drug Market?

Tablet formulations accounted for the largest market share in 2023.

5. Who are the key market players in the Global Meloxicam Drug Market?

Key players include Boehringer Ingelheim, Teva, Mylan, Hikma, Pfizer, Zydus, Sun Pharma, and Dr. Reddy’s Laboratories.